Physician profile
Ketan D Doshi
NPI 1750573069
$119,224.83
in general payments reported to CMS, 2019-2025
95 companies · $15K in 2025
The $15K reported for 2025 was more than what 85% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $22K · 2020: $16K · 2021: $13K · 2022: $24K · 2023: $11K · 2024: $18K · 2025: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $26K · Food and Beverage: $12K · Travel and Lodging: $3,454 · Long Term Medical Supply Or Device Loan: $1,863 · Education: $195.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $26,231.00 |
| Food and Beverage | $12,101.42 |
| Travel and Lodging | $3,453.61 |
| Long Term Medical Supply Or Device Loan | $1,863.04 |
| Education | $194.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $14,556.76 | 2019-2025 | Tagrisso, Imfinzi, Enhertu |
| Bayer Healthcare Pharmaceuticals INC. | $10,932.03 | 2019-2025 | |
| Gilead Sciences, INC. | $8,579.26 | 2021-2025 | Trodelvy |
| Novartis Pharmaceuticals Corporation | $8,407.18 | 2019-2025 | Promacta |
| Glaxosmithkline, LLC. | $6,327.97 | 2020-2025 | Ojjaara, Jemperli, Zejula |
| Celgene Corporation | $5,440.09 | 2019-2025 | Reblozyl, Pomalyst |
| Tesaro, INC. | $4,848.96 | 2019 | |
| Beigene USA, INC. | $4,458.29 | 2020-2025 | Brukinsa, Tevimbra |
| E.R. Squibb & Sons, L.L.C. | $4,110.73 | 2019-2025 | Opdivo, Opdualag, Krazati |
| Ipsen Biopharmaceuticals, INC | $4,090.73 | 2019-2025 | Onivyde, Somatuline Depot |
| Agios Pharmaceuticals, INC. | $3,979.54 | 2019-2020 | |
| Janssen Biotech, INC. | $3,778.55 | 2019-2025 | Tecvayli, Rybrevant, Erleada |
| Pharmacosmos Therapeutics INC. | $2,895.94 | 2020-2024 | Cosela |
| Incyte Corporation | $2,846.95 | 2021-2025 | Jakafi, Monjuvi |
| Astellas Pharma US INC | $2,742.20 | 2019-2025 | Xtandi, Padcev, Xospata |
Show all 94 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novocure INC. | $2,693.41 | 2020-2025 | Optune Lua (Novottf-200t), Optune |
| Cti Biopharma Corp. | $2,465.38 | 2023 | Vonjo |
| Argenx US, INC. | $2,200.00 | 2023 | Vyvgart |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,967.58 | 2019-2025 | |
| Pfizer INC. | $1,959.81 | 2019-2025 | |
| Heron Therapeutics, INC. | $1,516.83 | 2020-2023 | Cinvanti |
| Taiho Oncology, INC. | $1,498.13 | 2019-2025 | |
| Epizyme, INC. | $1,458.11 | 2020-2023 | Tazverik |
| Merck Sharp & Dohme LLC | $1,223.58 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Coherus Oncology, INC. | $1,013.02 | 2021-2025 | Loqtorzi, Udenyca |
| Daiichi Sankyo INC. | $944.29 | 2019-2025 | Enhertu, Enhertu, Injectafer |
| Seagen INC. | $872.74 | 2019-2025 | Tukysa, Adcetris, Tivdak |
| Lilly USA, LLC | $783.90 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
| Eisai INC. | $732.96 | 2019-2025 | |
| Amgen INC. | $693.59 | 2019-2023 | Lumakras, Kyprolis, Blincyto |
| Emd Serono, INC. | $689.75 | 2019-2025 | Bavencio |
| Puma Biotechnology, INC. | $656.15 | 2020-2024 | Nerlynx |
| Acceleron Pharma, INC. | $650.00 | 2021 | |
| Genentech USA, INC. | $556.92 | 2019-2025 | Venclexta, Polivy, Gazyva |
| Takeda Pharmaceuticals U.S.A., INC. | $519.11 | 2019-2025 | Fruzaqla, Alunbrig, Iclusig |
| Pharmacyclics LLC, An Abbvie Company | $419.12 | 2019-2023 | Imbruvica |
| Jazz Pharmaceuticals INC. | $407.20 | 2019-2025 | Zepzelca |
| Genzyme Corporation | $326.46 | 2019-2025 | |
| Genmab U.S., INC. | $287.38 | 2023-2025 | Epkinly |
| Janssen Pharmaceuticals, INC | $249.21 | 2022-2024 | Xarelto |
| Array Biopharma INC | $242.01 | 2019-2025 | Mektovi, Braftovi, Lorbrena |
| Octapharma USA, INC. | $209.18 | 2021-2024 | Panzyga, Octagam Immune Globulin (Human) |
| Abbvie INC. | $191.85 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $190.18 | 2019-2025 | Libtayo |
| Kite Pharma, INC. | $160.68 | 2020-2025 | Yescarta |
| Alexion Pharmaceuticals, INC. | $157.84 | 2019-2025 | Ultomiris |
| Fennec Pharmaceuticals, INC. | $155.24 | 2025 | Fyarro |
| Rigel Pharmaceuticals, INC. | $152.03 | 2021-2023 | Rezlidhia, Tavalisse |
| Stemline Therapeutics INC. | $151.49 | 2023-2025 | Orserdu |
| Tersera Therapeutics LLC | $147.43 | 2019-2025 | Zoladex, Quzyttir |
| Mirati Therapeutics, INC. | $146.73 | 2023-2024 | Krazati |
| Sobi, INC | $132.42 | 2022-2025 | |
| Beone Medicines USA, INC. | $130.63 | 2025 | Tevimbra, Brukinsa |
| Kyowa Kirin, INC. | $126.96 | 2019-2024 | Poteligeo |
| Stryker Corporation | $124.78 | 2021 | |
| Menarini Silicon Biosystems, INC. | $121.72 | 2024-2025 | |
| Janssen Scientific Affairs, LLC | $115.74 | 2020-2023 | Rybrevant, Pipeline |
| Aveo Pharmaceuticals, INC. | $112.69 | 2021-2024 | Fotivda |
| Sun Pharmaceutical Industries INC. | $102.23 | 2020-2025 | |
| Morphosys, US INC. | $100.63 | 2021-2023 | Monjuvi |
| Servier Pharmaceuticals LLC | $98.42 | 2021-2025 | |
| Tg Therapeutics, INC. | $97.18 | 2021-2022 | |
| Adc Therapeutics America, INC. | $89.49 | 2021-2024 | |
| Amneal Pharmaceuticals LLC | $74.01 | 2024 | Avastin, Neupogen, Neulasta |
| Apellis Pharmaceuticals, INC. | $73.85 | 2023-2024 | Empaveli |
| Caris Mpi, INC. | $72.00 | 2025 | Mi Cancer Seek |
| Csl Behring | $62.64 | 2021-2024 | Afstyla, Idelvion |
| Exelixis INC. | $59.21 | 2019-2024 | Cabometyx |
| G1 Therapeutics, INC. | $58.87 | 2022 | |
| Foundation Medicine, INC. | $55.85 | 2019-2021 | |
| Pharmaessentia USA Corporation | $50.40 | 2023-2025 | Besremi |
| Tempus Ai, INC | $48.57 | 2024-2025 | Xt Cdx |
| Astellas Pharma Global Development | $48.30 | 2019 | |
| Adaptive Biotechnologies Corporation | $46.94 | 2025 | Clonoseq |
| Lexicon Pharmaceuticals, INC. | $46.58 | 2019-2020 | |
| Acelrx Pharmaceuticals, INC. | $44.73 | 2021 | |
| Secura Bio, INC. | $42.45 | 2019-2022 | |
| Dova Pharmaceuticals | $37.77 | 2020-2021 | |
| Karyopharm Therapeutics INC. | $37.76 | 2022 | |
| Geron Corporation | $37.07 | 2025 | Rytelo |
| Immunocore Limited | $36.18 | 2023 | Kimmtrak |
| Horizon Therapeutics Plc | $32.13 | 2019 | |
| Immunogen, INC. | $28.86 | 2023 | Elahere |
| Alnylam Pharmaceuticals INC. | $24.36 | 2022 | |
| Syndax Pharmaceuticals, INC. | $23.98 | 2025 | |
| Springworks Therapeutics, INC. | $22.21 | 2025 | Ogsiveo |
| Medtronic, INC. | $19.58 | 2022 | |
| Ge Healthcare | $17.77 | 2022 | |
| Ferring Pharmaceuticals INC. | $17.56 | 2025 | Adstiladrin |
| Emmaus Medical, INC. | $15.75 | 2019 | |
| Clovis Oncology, INC. | $15.36 | 2019 | |
| Blueprint Medicines Corporation | $13.50 | 2022 | |
| Dendreon Pharmaceuticals LLC | $12.08 | 2019 | |
| Sanofi-Aventis U.S. LLC | $11.15 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$8,450.00 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ketan Doshi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.